Satsuma Pharmaceuticals, Inc.
STSADelisted Jun 8, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001692830
Satsuma Pharmaceuticals, Inc. was delisted on Jun 8, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 31 institutions reported holding it in 13F filings for Q1 2023, worth $12.7M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Satsuma Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Satsuma Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| RA Capital Healthcare Fund LP | Other: Former 10% Owner | 0Indirect | Jun 12, 2023 | 0 |
| Ra Capital Management, L.P. | Other: Former 10% Owner | 0Indirect | Jun 12, 2023 | 0 |
| Kolchinsky Peter | Other: Former 10% Owner | 0Indirect | Jun 12, 2023 | 0 |
| King Thomas Braxton | Director | – | Jun 8, 2023 | 0 |
| Kollins John A | President and CEO | 0 | Jun 8, 2023 | 0 |
| Soloway Thomas P | Director | – | Jun 8, 2023 | 0 |
| Lukatch Heath | Director | – | Jun 8, 2023 | 0 |
| Shah Rajeev M. | Director, 10% Owner | 0Indirect | Jun 8, 2023 | 0 |
| Sandoval Elisabeth | Director | – | Jun 8, 2023 | 0 |
| O'Neil Thomas P. | Chief Financial Officer | 0 | Jun 8, 2023 | 0 |
| Takanashi Ken | Director, 10% Owner | 24,847,694Indirect | Jun 8, 2023 | 0 |
| Shin Nippon Biomedical Laboratories, Ltd. | 10% Owner | 8,423,732Indirect | Jun 8, 2023 | 0 |
| Harsch Mutya | Director | – | Jun 8, 2023 | 0 |
| Riebe Michael T | Director | – | Jun 8, 2023 | 0 |
| Leonard Braden Michael | 10% Owner | 150,000 | Nov 23, 2022 | 0 |
| Commodore Capital LP | 10% Owner | 461,286Indirect | Nov 16, 2022 | 0 |
| Albrecht Detlef | Chief Medical Officer | – | Jun 7, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2023 (view filing) | Jun 6 | 2 days | Takanashi KenDirector, 10% Owner | PPurchaseCommon Stock, $0.0001 par value | +22.1M | $0.91 | +$20.1M | +789.3%24.8M after | |
| Jun 8, 2023 (view filing) | Jun 6-8 | 2 days | Shin Nippon Biomedical Laboratories, Ltd.10% Owner | PPurchase | +30.5M | $0.91 | +$27.7M | New position8.42M after | 2 lots |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +150.0K | $0.71 | +$106.5K | New position150.0K after | |
| Nov 16, 2022 (view filing) | Nov 14-15 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +6.44M | $0.6823 | +$4.39M | New position6.44M after | 3 lots |
| Nov 16, 2022 (view filing) | Nov 14 | 2 days | Commodore Capital LP10% Owner | SSaleCommon Stock, par value $0.0001 per share | −3.25M | $0.71 | −$2.31M | −87.6%461.3K after | |
| Nov 29, 2021 (view filing) | Nov 24 | 5 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +2.92K | $5.42 | +$15.8K | +0.1%3.71M after | |
| Nov 23, 2021 (view filing) | Nov 19-22 | 4 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +13.2K | $5.48 | +$72.3K | +0.4%3.71M after | 2 lots |
| Nov 12, 2021 (view filing) | Nov 10-11 | 2 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +17.6K | $5.94 | +$104.3K | +0.5%3.70M after | 2 lots |
| Nov 10, 2021 (view filing) | Nov 8 | 2 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +560 | $5.99 | +$3.35K | 0.0%3.68M after | |
| Nov 8, 2021 (view filing) | Nov 4-5 | 4 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +9.20K | $5.94 | +$54.6K | +0.3%3.68M after | 2 lots |
| Nov 4, 2021 (view filing) | Nov 2 | 2 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +8.88K | $5.64 | +$50.1K | +0.2%3.67M after | |
| Nov 2, 2021 (view filing) | Oct 29 | 4 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +44.7K | $5.71 | +$255.0K | +1.2%3.66M after | |
| Oct 29, 2021 (view filing) | Oct 27-28 | 2 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +54.7K | $5.48 | +$299.4K | +1.5%3.61M after | 2 lots |
| Oct 25, 2021 (view filing) | Oct 21-22 | 4 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +60.4K | $5.45 | +$329.4K | +1.7%3.56M after | 2 lots |
| Oct 21, 2021 (view filing) | Oct 19-20 | 2 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +128.2K | $5.19 | +$665.2K | +3.8%3.50M after | 2 lots |
| Oct 19, 2021 (view filing) | Oct 15-18 | 4 days | Commodore Capital LP10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +162.2K | $4.84 | +$784.8K | +5.1%3.37M after | 2 lots |